The FDA has approved Pfizer‘s Selzentry tablets, the first in a new class of oral HIV medicines in more than 10 years, according to the marketer. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. Selzentry is expected to be available in the U.S. by the middle of September. The FDA granted accelerated approval to Selzentry for combination antiretrovira...